Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

May 30, 2023

Primary Completion Date

July 1, 2028

Study Completion Date

July 1, 2028

Conditions
Multiple MyelomaRelapse Multiple Myeloma
Interventions
DRUG

Belantamab mafodotin

Cycles 1, 3, 5, 7, etc. (odd numbered cycles): 1.9 mg/kg IV on Day 1 (28-day cycles)

DRUG

Carfilzomib

"Cycle 1: 20 mg/m2 on Day 1, then 56 mg/m2 on Days 8/15~Cycles 2-8: 56 mg/m2 on Days 1/8/15~Cycles 9+: 56 mg/m2 on Days 1/15"

DRUG

Pomalidomide

3 mg Day 1-21 of 28-day Cycle

DRUG

Dexamethasone

"Cycles 1-4: 40 mg Days 1/8/15/22~Cycles 5+: 20 mg Days 1/8/15/22"

Trial Locations (1)

60637

RECRUITING

University of Chicago Medicine Comprehensive Cancer Center, Chicago

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Amgen

INDUSTRY

lead

University of Chicago

OTHER

NCT05789303 - Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma | Biotech Hunter | Biotech Hunter